Guidelines on the Management of Stable Angina Pectoris ... - Cardio

58 ESC <strong>Guidelines</strong>458. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and bloodpressure reduction: a quantitative overview updated until 1 March2003. J Hypertens 2003;21:1055–1076.459. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MHet al. Health outcomes associated with various antihypertensivetherapies used as first-line agents: a network meta-analysis. JAMA2003;289:2534–2544.460. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of anangiotensin-converting-enzyme inhibitor, ramipril, on cardiovascularevents in high-risk patients. The Heart Outcomes PreventionEvaluation Study Investigators. N Engl J Med 2000;342:145–153.461. Fox KM. Efficacy of perindopril in reduction of cardiovascular eventsamong patients with stable coronary artery disease: randomised,double-blind, placebo-controlled, multicentre trial (the EUROPAstudy). Lancet 2003;362:782–788.462. Gustafsson I T-PC, Kober L, Gustafsson F HP. Effect of the angiotensinconvertingenzyme inhibitor trandopril on mortality and morbidity indiabetic patients with left ventricular dysfunction after acute myocardialinfarction. Trace Study Group. 1999;34:83–89.463. Luft FC. Recent clinical trial highlights in hypertension. Curr HypertensRep 2001;3:133–138.464. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparativeeffects of ramipril on ambulatory and office blood pressures: a HOPESubstudy. Hypertension 2001;38:E28–E32.465. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. Theeffect of perindopril on cardiovascular morbidity and mortality inpatients with diabetes in the EUROPA study: results from the PERSUADEsubstudy. Eur Heart J 2005;26:1369–1378.466. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevanceof usual blood pressure to vascular mortality: a meta-analysisof individual data for one million adults in 61 prospective studies.Lancet 2002;360:1903–1913.467. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al.Effect of antihypertensive agents on cardiovascular events in patientswith coronary disease and normal blood pressure: the CAMELOT study:a randomized controlled trial. JAMA 2004;292:2217–2225.468. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al.Outcomes in hypertensive patients at high cardiovascular risk treatedwith regimens based on valsartan or amlodipine: the VALUE randomisedtrial. Lancet 2004;363:2022–2031.469. Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M et al.Role of blood pressure and other variables in the differential cardiovascularevent rates noted in the Anglo-Scandinavian CardiacOutcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet2005;366:907–913.470. Staessen J, Birkenhager WH. Evidence that new antihypertensives aresuperior to older drugs. Lancet 2005;366:869–871.471. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment withdrugs to lower blood pressure and blood cholesterol based on an individual’sabsolute cardiovascular risk. Lancet 2005;365:434–441.472. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR et al.Emerging role of angiotensin-converting enzyme inhibitors in cardiacand vascular protection. Circulation 1994;90:2056–2069.473. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni APet al. Valsartan, captopril, or both in myocardial infarction complicatedby heart failure, left ventricular dysfunction, or both. N Engl J Med2003;349:1893–1906.474. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al.Effects of candesartan in patients with chronic heart failure and preservedleft-ventricular ejection fraction: the CHARM-Preserved Trial.Lancet 2003;362:777–781.475. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al.Randomized trial of estrogen plus progestin for secondary preventionof coronary heart disease in postmenopausal women. Heart andEstrogen/progestin Replacement Study (HERS) Research Group. JAMA1998;280:605–613.476. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky Met al. Cardiovascular disease outcomes during 6.8 years of hormonetherapy: Heart and Estrogen/progestin Replacement Study follow-up(HERS II). JAMA 2002;288:49–57.477. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C,Stefanick ML et al. Risks and benefits of estrogen plus progestin inhealthy postmenopausal women: principal results From the Women’sHealth Initiative randomized controlled trial. JAMA 2002;288:321–333.478. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL et al.Estrogen plus progestin and the risk of coronary heart disease. NEnglJ Med 2003;349:523–534.479. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausalhormone therapy: annual trends and response to recent evidence.JAMA 2004;291:47–53.480. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinicaltrials in heart disease. I. Treatments following myocardial infarction.JAMA 1988;260:2088–2093.481. Freemantle N, Urdahl H, Eastaugh J, Hobbs FD. What is the place ofbeta-blockade in patients who have experienced a myocardial infarctionwith preserved left ventricular function? Evidence and (mis)interpretation.Prog Cardiovasc Dis 2002;44:243–250.482. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it awise choice? Lancet 2004;364:1684–1689.483. Hjemdahl P, Eriksson SV, Held C, Forslund L, Nasman P, Rehnqvist N.Favourable long term prognosis in stable angina pectoris: an extendedfollow up of the angina prognosis study in Stockholm (APSIS). Heart2006;92(2):177–182. [EPub ahead of print June 10, 2005]484. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA et al.Effects of treatment on outcome in mildly symptomatic patients withischemia during daily life. The Atenolol Silent Ischemia Study (ASIST).Circulation 1994;90:762–768.485. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XLRandomised Intervention Trial in Congestive Heart Failure (MERIT-HF).Lancet 1999;353:2001–2007.486. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomisedtrial. Lancet 1999;353:9–13.487. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al.The effect of carvedilol on morbidity and mortality in patients withchronic heart failure. U.S. Carvedilol Heart Failure Study Group.N 0Engl J Med 1996;334:1349–1355.488. Effect of verapamil on mortality and major events after acute myocardialinfarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am JCardiol 1990;66:779–785.489. The Multicenter Diltiazem Postinfarction Trial Research Group. Theeffect of diltiazem on mortality and reinfarction after myocardialinfarction. N Engl J Med 1988;319:385–392.490. Boden WE, van Gilst WH, Scheldewaert RG, Starkey IR, Carlier MF, JulianDG et al. Diltiazem in acute myocardial infarction treated with thrombolyticagents: a randomised placebo-controlled trial. IncompleteInfarction Trial of European Research Collaborators EvaluatingPrognosis post-Thrombolysis (INTERCEPT). Lancet 2000;355:1751–1756.491. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase inmortality in patients with coronary heart disease. Circulation1995;92:1326–1331.492. Stason WB, Schmid CH, Niedzwiecki D, Whiting GW, Caubet JF, Cory Det al. Safety of nifedipine in angina pectoris: a meta-analysis.Hypertension 1999;33:24–31.493. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G,Danchin N et al. Effect of long-acting nifedipine on mortality and cardiovascularmorbidity in patients with stable angina requiring treatment(ACTION trial): randomised controlled trial. Lancet 2004;364:849–857.494. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK et al.Meta-analysis of trials comparing beta-blockers, calcium antagonists,and nitrates for stable angina. JAMA 1999;281:1927–1936.495. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N EnglJ Med 1998;338:520–531.496. Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stableangina pectoris. Cardiovasc Drugs Ther 1994;8:611–623.497. ISIS-4 (Fourth International Study of Infarct Survival) CollaborativeGroup. ISIS-4: a randomised factorial trial assessing early oral captopril,oral mononitrate, and intravenous magnesium sulphate in 58,050patients with suspected acute myocardial infarction. Lancet1995;345:669–685.498. Gruppo Italiano per lo Studio della Sopravvivenza nell’infartoMiocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitratesingly and together on 6-week mortality and ventricular functionafter acute myocardial infarction. Lancet 1994;343:1115–1122.499. Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patchesfor stable angina pectoris. Cardiovasc Drugs Ther 1994;8:625–633.500. Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermalnitroglycerin therapy. Decreased anginal threshold during the nitratefreeinterval. Circulation 1995;91:973–978.501. Pepine CJ, Lopez LM, Bell DM, Handberg-Thurmond EM, Marks RG,McGorray S. Effects of intermittent transdermal nitroglycerin on